NCT02065245View on ClinicalTrials.gov

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 3, 2014

Primary Completion Date

October 2, 2019

Study Completion Date

October 2, 2020

Conditions
Frailty
Interventions
BIOLOGICAL

Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)

Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion

BIOLOGICAL

Placebo

Placebo administered by peripheral intravenous infusion.

BIOLOGICAL

Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)

Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.

Trial Locations (1)

33136

ISCI/University of Miami Miller School of Medicine, Miami

Sponsors

Lead Sponsor

Longeveron Inc.
All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

Longeveron Inc.

INDUSTRY

NCT02065245 - AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery | Biotech Hunter | Biotech Hunter